Back to results
US 12,121,616 B2Granted
Transdermal therapeutic system for the transdermal administration of solifenacin
AssigneeLTS Lohmann Therapie-Systeme AG
InventorsGabriel Wauer, Frank Seibertz
Life of this patent
Estimating the term…
Abstract
The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.
Claims21
A transdermal therapeutic system for the transdermal administration of solifenacin comprising a solifenacin-containing layer structure,
- the solifenacin-containing layer structure comprising:
- A) a backing layer, and
- B) a solifenacin-containing layer comprising a therapeutically effective amount of solifenacin base,
- wherein the solifenacin-containing layer structure comprises at least one polymer selected from the group consisting of a polymer based on polysiloxanes, a silicone acrylic hybrid polymer, a polymer based on polyisobutylenes, and an acrylate polymer, and wherein the transdermal therapeutic system does not contain a transdermal permeation enhancer selected from the group consisting of a fatty acid ester, a terpene, and a carboxylic acid having 2 to 10 carbon atoms;
- and
- wherein the transdermal therapeutic system releases more than 25% of the solifenacin base contained in the transdermal therapeutic system over a period of administration of 72 hours.
3 more elements
A transdermal therapeutic system for the transdermal administration of solifenacin comprising a solifenacin-containing layer structure,
- the solifenacin-containing layer structure comprising:
- A) a backing layer;
- and
- B) a solifenacin-containing matrix layer,
- wherein the solifenacin-containing matrix layer comprises:
- a) a therapeutically effective amount of solifenacin base;
- and
- b) at least one polymer, wherein the polymer is a polymer based on polysiloxanes, a silicone acrylic hybrid polymer, or a combination thereof,
- wherein the transdermal therapeutic system does not contain a fatty acid ester, a terpene, and a carboxylic acid having 2 to 10 carbon atoms, and
- wherein the transdermal therapeutic system releases more than 25% of the solifenacin base contained in the transdermal therapeutic system over a period of administration of 72 hours.
7 more elements
A transdermal therapeutic system for the transdermal administration of solifenacin comprising a solifenacin-containing layer structure,
- the solifenacin-containing layer structure comprising:
- A) a backing layer;
- and
- B) a solifenacin-containing matrix layer,
- wherein the solifenacin-containing matrix layer comprises:
- a) a therapeutically effective amount of solifenacin base;
- b) at least one polymer, wherein the polymer is a polymer based on polysiloxanes, a silicone acrylic hybrid polymer, or a combination thereof;
- and
- c) a further polymer, wherein the further polymer is a polymer based on polysiloxanes, a silicone acrylic hybrid polymer, an acrylate polymer, or a combination thereof,
- wherein the transdermal therapeutic system does not contain a fatty acid ester, a terpene, and a carboxylic acid having 2 to 10 carbon atoms;
- and
- wherein the transdermal therapeutic system releases more than 25% of the solifenacin base contained in the transdermal therapeutic system over a period of administration of 72 hours.
9 more elements
Dependencies are inferred from the claim text.